Rheumatology International

, Volume 32, Issue 11, pp 3619–3624 | Cite as

Appraising osteoporosis care gaps

  • Thomas P. Olenginski
  • Jana L. Antohe
  • Elaine Sunderlin
  • Thomas M. Harrington
Original Article

Abstract

To evaluate physician response to dual-energy X-ray absorptiometry (DXA) report within the Geisinger Medical Center’s Mobile DXA Program and treatment adherence at 1 year. Between 10/01/2004 and 3/30/2005, 1381 DXA scans were performed in our Mobile DXA Program. Within this cohort, we identified 366 high-risk, drug-naive patients and report the percentage of patients placed on prescription drug therapy within 90 days of DXA result. Additionally, we identified 191 patients with Z-score of −1.0 or worse and report whether laboratory tests were ordered within 90 days of DXA results in this group. Finally, we determined treatment adherence at 1 year. 269 patients (74%) were offered prescription therapy within 3 months of DXA results. Of those, 210 (57%) were still adherent to drug therapy at 1 year. The main reason for discontinuation of treatment was an adverse drug side effect. Additionally, in 50% cases, physicians ordered 1 or more laboratory tests to evaluate low Z-score. Within our Mobile DXA Program, 74% of high-risk, drug-naïve patients were treated. Interestingly, in 50% cases, when a low Z-score was reported, our physicians ordered 1 or more laboratory tests. Treatment adherence was 57% at 1 year.

Keywords

Osteoporosis DXA Osteoporosis care gap Fracture risk Treatment adherence Bisphosphonates Glucocorticoid induced osteoporosis program 

References

  1. 1.
    Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King AB, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States. J Bone Miner Res 22:465–475PubMedCrossRefGoogle Scholar
  2. 2.
    Dawson-Hughes B, Tosteson A, Melton LJ et al (2008) Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporosis Int. doi:10.1007/s00198-008-0559-5
  3. 3.
    National Osteoporosis Foundation (2008) Clinician’s guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, WashingtonGoogle Scholar
  4. 4.
    Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535–1541PubMedCrossRefGoogle Scholar
  5. 5.
    Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 280:2077–2082Google Scholar
  6. 6.
    Reginster J, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83–91PubMedCrossRefGoogle Scholar
  7. 7.
    Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 282:1344–1352PubMedCrossRefGoogle Scholar
  8. 8.
    Chesnut CH III, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241–1249CrossRefGoogle Scholar
  9. 9.
    Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial: multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA 282:637–645PubMedCrossRefGoogle Scholar
  10. 10.
    Chestnut CH III, Silverman S, Andriano K et al (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 109:267–276CrossRefGoogle Scholar
  11. 11.
    Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. NEJM 344:1434–1441PubMedCrossRefGoogle Scholar
  12. 12.
    Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. NEJM 356:1809–1822PubMedCrossRefGoogle Scholar
  13. 13.
    Giangregorio L, Papaioannou A, Cranney A, Zytaruk N, Adachi JD (2006) Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthr Rheum 35:293–305CrossRefGoogle Scholar
  14. 14.
    Rosen CJ, Brown SA (2005) A rationale approach to evidence gaps in the management of osteoporosis. Am J Med 118:1183–1189PubMedCrossRefGoogle Scholar
  15. 15.
    Majumdar SR, Kim N, Colman I et al (2005) Incidental vertebral fractures discovered with chest radiography in the emergency department. Arch Intern Med 165:905–909PubMedCrossRefGoogle Scholar
  16. 16.
    Andrade SE, Majumdar SR, Chan A et al (2003) Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med 163:2052–2057PubMedCrossRefGoogle Scholar
  17. 17.
    Cuddihy MT, Gabriel SE, Crowson CS et al (2002) Osteoporosis intervention following distal forearm fractures. Arch Intern Med 162:421–426PubMedCrossRefGoogle Scholar
  18. 18.
    Pullman-Mooar S, Mooar P (2005) Osteoporosis treatment after hip fracture: slow progress. J Clin Rheumatol 11:65–66PubMedCrossRefGoogle Scholar
  19. 19.
    Kamel HK (2005) Secondary prevention of hip fractures among the hospitalized elderly—are we doing enough? J Clin Rheumatol 11:68–71PubMedCrossRefGoogle Scholar
  20. 20.
    Majumdar SR, Beaupre LA, Harley CH et al (2007) Use of a case manager to improve osteoporosis treatment after hip fracture. Arch Intern Med 167:2110–2115PubMedCrossRefGoogle Scholar
  21. 21.
    Kaufman JD, Bolander ME, Bunta AD et al (2003) Barriers and solutions to osteoporosis care in patients with a hip fracture. J Bone Joint Surg 85:1837–1843PubMedGoogle Scholar
  22. 22.
    Felstein A, Elmer PJ, Orwoll E, Herson M, Hillier T (2003) Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures. Arch Intern Med 163:2165–2172CrossRefGoogle Scholar
  23. 23.
    Crilly RG, McKercher HG, Hindman D, Pavlakovic R, Kloseck M (2003) Prevention of fractures in the long-term care population: the gap between evidence and practice, Geriatrics Today. J Can Geriatr Soc 6:16–20Google Scholar
  24. 24.
    McNearney TA, Shepherd AJ, Chhabra A, Goel N (2006) Primary care house staff attitudes toward osteoporosis management. South Med J 99:461–466PubMedCrossRefGoogle Scholar
  25. 25.
    Juby AG, De Geus-Wenceslau CM (2002) Evaluation of osteoporosis treatment in seniors after hip fracture. Osteoporos Int 13:205–210PubMedCrossRefGoogle Scholar
  26. 26.
    Papaioannou A, Kennedy C, Ioannidis G et al (2008) The osteoporosis care gap in men with fragility fractures: the Canadian multicentre osteoporosis study. Osteoporos Int 19:581–587PubMedCrossRefGoogle Scholar
  27. 27.
    Newman ED, Starkey R, Ayoub W, Gutknecht D, Hanus P, Davis C, Diehl J, Neuner M (2000) Osteoporosis clinical practice guideline, 2nd edn. Penn State Geisinger Health System, USAGoogle Scholar
  28. 28.
    Newman ED, Olenginski TP, Perruquet JL, Hummel J, Indeck C, Wood GC (2004) Using mobile DXA to improve access to osteoporosis care. J Clin Densitom 7:71–75PubMedCrossRefGoogle Scholar
  29. 29.
    National Osteoporosis Foundation (2003) Physician’s guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, WashingtonGoogle Scholar
  30. 30.
    Solomon DH, Morris C, Cheng H et al (2005) Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions. Mayo Clin Proc 80:194–202PubMedCrossRefGoogle Scholar
  31. 31.
    Bloui J, Dragomir A, Ste-Marie L-G, Fernandes JC, Perreault S (2007) Discontinuation of antiresorptive therapies: a comparison between 1998–2001 and 2002–2004 among osteoporotic women. J Clin Endocrinol Metab 92:887–894Google Scholar
  32. 32.
    Baim S (2008) Official positions of the International society for clinical densitometry and executive summary of the 2007 ISCD position development conference. J Clin Densitom 11:75–91PubMedCrossRefGoogle Scholar
  33. 33.
    Olenginski TP, Newman ED, Hummel JL, Hummer M (2006) Development and evaluation of a vertebral fracture assessment program using IVA and its integration with Mobile DXA. J Clin Densitom 9:72–77Google Scholar
  34. 34.
    Stock JL, Waud CE, Coderre JA et al (1998) Clinical reporting to primary care physicians leads to increased use and understanding of bone densitometry and affects the management of osteoporosis. Ann Int Med 128:996–999PubMedGoogle Scholar
  35. 35.
    Tannenbaum C, Clark J, Schwartzman K et al (2002) Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 87:4431–4437PubMedCrossRefGoogle Scholar
  36. 36.
    Holick M (2006) High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 81(3):353–373PubMedCrossRefGoogle Scholar
  37. 37.
    Newman ED, Matzko CK, Olenginski TP et al (2006) Glucocorticoid-induced osteoporosis program (GIOP): a novel, comprehensive, and highly successful program with improved outcomes at 1 year. Osteoporos Int 17:1428–1434PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Thomas P. Olenginski
    • 1
  • Jana L. Antohe
    • 1
  • Elaine Sunderlin
    • 2
  • Thomas M. Harrington
    • 1
  1. 1.Department of RheumatologyGeisinger Medical CenterDanvilleUSA
  2. 2.Department of Internal MedicineUniversity of North CarolinaChapel HillUSA

Personalised recommendations